Categories
Blog

China’s New Drug Pricing Architecture: What It Means for Manufacturers

Key takeaways on launch pricing, role of commercial insurance, and real-world evidence, based on payer interviews

Document 9 (国办发〔2026〕9号, “Opinions on Improving the Drug Price Formation Mechanism”), issued by the State Council General Office in April 2026, is China’s latest overhaul of drug pricing policy. Rather than introducing a single new rule, it provides a framework that formalizes and connects mechanisms already taking shape. A June 2026 draft implementing notice has begun to clarify the details of launch pricing, which are incorporated here. Access Infinity has consulted its payer network in China to explore three key elements of the framework and their implications for manufacturers: the new launch pricing mechanism, the growing role of commercial insurance, and the use of real-world evidence (RWE) in price revisions.

Launch pricing: earlier scrutiny, and a shorter window

The June 2026 draft implementing notice groups new drugs into three tiers based on an innovation-value score. Drugs with genuinely new mechanisms or targets can receive up to 60 points (50 for biologics), derivatives or new routes of administration can receive 30 points, and clinical benefit can contribute up to 25 points. CAR-T products automatically qualify for the “new mechanism” category, a favorable provision for cell-therapy manufacturers. Only drugs with genuine first-in-class innovation can exceed 100 points and qualify for free pricing during the self-pay period. Most new drugs are likely to fall within the more constrained 50–100-point tier, where launch prices are determined by comparison with similar existing products. Drugs scoring below 50 points must be priced at parity with existing comparators.

Even top-tier drugs do not have indefinite pricing freedom. Each tier has a limited “price stability period”: 3–6 years for drugs scoring above 100 points, 2–5 years for those scoring 50–100 points, and none for those below 50 points. After this period, manufacturers must submit a price-adjustment plan based on actual sales and value data or face an automatic reduction of at least 25%. The 50–100-point tier faces further restrictions: prices are capped against reference drugs, whose prices may themselves decline. Manufacturers must also disclose costs to NHSA and may receive a public “yellow-label” warning for substantial price gaps versus reference drugs.

For manufacturers, the new mechanism means greater price scrutiny even without NRDL inclusion. Setting a high launch price to allow room for a later “discount” during NRDL negotiations is therefore likely to become less effective: mid-tier (50–100-point) prices are tied to reference drugs, while top-tier (above 100-point) pricing freedom is time-limited. Building a defensible clinical-value case earlier in development will become more important. This includes selecting the hospital that leads pivotal trials, as the draft explicitly prioritizes the views of institutions that conducted the drug’s own clinical research when NHSA reviews a manufacturer’s self-assessed price. For mid-tier drugs whose launch prices have already been constrained by comparators, discounts at subsequent NRDL negotiations are expected to be smaller than they are today.

Note: The draft implementing notice, reported by Latitude Health via Huxiu on June 17, 2026, was circulated for public comment. Its final form and implementation timeline remain unconfirmed.

“By the time you go to enter NRDL, they'll basically just reference [your launch] price — they won't negotiate with you again... It might be adjusted, but not by much, because your launch price is already considered a reasonable one."
Former member, clinical and economic advisor to the NRDC, Professor of Health Policy and Management

Commercial insurance: an increasingly important track

Document 9 also encourages commercial insurance to serve as a complementary payer. This approach was already evident in last year’s 19-product “Category C” innovative-drug catalogue and has now been elevated to this year’s government work report. High-priced drugs that do not secure NRDL inclusion through negotiation may first obtain commercial coverage and potentially enter NRDL later if manufacturers reduce their prices.

For manufacturers, this represents a meaningful, though still limited, channel. Of the roughly 19 products admitted to the catalogue last year, most gained traction through city-level “Huiminbao” supplementary schemes rather than mainstream commercial insurance. Nevertheless, inclusion offers tangible benefits, including dual-channel pharmacy access in some provinces and DRG exemptions. Category C inclusion also serves as a public endorsement from NHSA, helping raise the profile of products that otherwise cannot be advertised. It is also increasing pressure on commercial insurers to participate. Manufacturers may be able to capitalize on this momentum: as Category C products gain clinical credibility, insurers that do not engage risk being bypassed and losing relevance. Commercial insurance is not yet a full alternative to NRDL access, but it is becoming a credible pathway in its own right, particularly for high-priced innovative drugs, newer indications not yet reimbursed, and legacy branded products facing pressure from centralized procurement after loss of exclusivity (LoE).

"Whether or not you choose to partner with Category C list starts to force a sense of crisis onto commercial insurers. If commercial insurance doesn't keep up, frankly, it will hollow-out and become irrelevant."
Former member of NHSA, with experience in private insurer

Real-world evidence: a pricing lever, at the cost of transparency

Document 9 also sets out a forward-looking RWE framework to inform price adjustments for drugs already included in NRDL or the Category C list. This introduces an “efficacy risk” dimension alongside an existing mechanism: financial-risk-based repricing at NRDL’s routine two-year renewal, which compares actual sales and insurance-fund spending with volumes committed during negotiation. By contrast, the proposed RWE approach would compare real-world clinical outcomes with the evidence available at the initial negotiation to assess whether a drug’s value had been underestimated or overestimated.

For manufacturers, RWE presents both an opportunity and a risk. On the positive side, it can generate evidence at a comparatively lower cost than a new randomized controlled trial (RCT). A favorable result endorsed by NHSA can also raise a drug’s profile when direct advertising is restricted. However, studies must be conducted through NHSA-designated “credible evaluation institutions” (currently around 79, with expansion through 14 pilot cities). Protocols are agreed in advance, and all results—positive or negative—must be reported to NHSA. Manufacturers bear both the study costs and the risk of unfavorable disclosures. Although NHSA encourages RWE generation, participation remains voluntary. The possibility of negative findings may help explain why only a handful of companies have explored this route so far, rather than making it standard practice.

“Using real clinical data generated after the drug enters NRDL to re-evaluate it makes complete sense… But in reality, the money has to come from the manufacturer, the risk falls on the manufacturer, and how much benefit it will ultimately bring is uncertain — so in practice, I think manufacturers will be very cautious about this."
Former member, clinical and economic advisor to the NRDC, Professor of Health Policy and Management

Summary

Across all three provisions, China’s new drug pricing architecture is less about loosening or tightening prices outright than about clarifying when and how manufacturers must demonstrate value: earlier, at launch; across more channels, with commercial insurance becoming a credible pathway; and on an ongoing basis, through real-world evidence. Pricing and evidence strategy can no longer revolve around a single negotiation. Instead, manufacturers need a multi-stage value narrative, with genuine first-in-class innovation increasingly providing the clearest route to meaningful pricing freedom.

Frequently Asked Questions

China’s new drug pricing framework introduces a more structured, innovation-based approach to launch pricing. Under the proposed system, medicines are assessed across three tiers based on their innovation and clinical value. First-in-class drugs may benefit from greater pricing flexibility, while others face tighter pricing controls based on existing comparators. Manufacturers will need stronger clinical evidence to justify prices at launch.

Commercial health insurance is becoming an increasingly important complement to China’s National Reimbursement Drug List (NRDL). The Category C innovative-drug catalogue creates additional opportunities for high-cost medicines to gain coverage through supplementary insurance schemes. Although commercial insurance is not yet a complete alternative to NRDL reimbursement, it offers manufacturers another potential route to patient access.

China’s evolving drug pricing framework aims to use real-world evidence (RWE) to reassess medicines based on their actual clinical outcomes. RWE could inform future price adjustments for drugs included in the NRDL or Category C catalogue, helping determine whether their demonstrated value matches initial expectations. While participation remains voluntary, manufacturers must consider the costs and disclosure risks of generating this evidence.

About the authors

Image of Isabel Rubio, Director at Access Infinity
Isabel Rubio

Isabel is a Partner at Access Infinity and has supported pharma companies in developing their Pricing & Market Access strategy for products across all major therapeutic areas. She’s worked with several orphan drug manufacturers from the earliest stages of drug development through to launch readiness, to ensure the value of their therapies is recognised by payers.

If you have a question or a project in mind, get in touch with Isabel by emailing isabel@accessinfinity.com or via our contact us page.

Dr Ruodan Nan

Ruodan is an Associate Consultant at Access Infinity with over four years of experience in market access and pricing, supporting both qualitative and quantitative projects across therapeutic areas including oncology, immunology, neurology, rare diseases, ophthalmology, and respiratory diseases. She has developed expertise in market access environments across multiple regions, with a special interest in China and Taiwan.​

If you have a question or a project in mind, get in touch with Ruodan by emailing ruodan@accessinfinity.com or via our contact us page.

Categories
Blog

GKV-BStabG is now law: Germany’s pharma rebate rises to 15.5% from January 2027

The Bundestag passed the GKV-BStabG on 10 July 2026, fixing the manufacturer rebate at 15.5% from 1 January 2027 with no phase-in. Here’s what changed between the draft and the final law, and what to do before budgets lock.

Germany’s GKV-BStabG (Beitragssatzstabilisierungsgesetz) cleared the Bundestag 319 to 286 on 10 July 2026, and the Bundesrat the same afternoon. The core pharma provisions take effect on 1 January 2027, with a handful of measures, including the removal of AMNOG price guardrails and the abolition of the combination discount, live from the day after promulgation in the Federal Law Gazette.

The final law replaces the draft’s open-ended dynamic rebate formula with a fixed rate. The manufacturer rebate rises from 7% to 15.5%, applied in full from day one, with no transitional period and no fixed expiry date.

What changed between the April draft and the final law

The manufacturer rebate was the most contested provision, and it changed the most. The April draft proposed a dynamic, formula-driven rebate that industry modelled at close to 20% by 2030. The Health Committee struck that formula and replaced it with a flat additional 8.5 percentage points on top of the existing 7% base, taking the total to 15.5% from 1 January 2027.

Two other provisions were tightened in committee: the volume-based fallback (scale factor up 50%) and the vaccine category rebate (raised from 7% to 9%, a stacked total of around 16%, plus a price freeze to 2030). The selective tendering pilot for patented drugs in five therapeutic classes and the combination discount abolition passed largely as drafted, as did the price moratorium extension to 31 December 2030.

Read the full analysis

 

Our full whitepaper covers all seven provisions as adopted against the April draft, the two positive changes for industry, portfolio-level guidance by company type and product type, the European price corridor implications for internationally referenced products, and a scenario-by-scenario action plan with dates through 2027.

Download the whitepaper

 

This blog is prepared by Access Infinity for informational purposes. All provisions described reflect the GKV-BStabG as passed on 10 July 2026 and stakeholder analysis current as of 23 July 2026. The Federal Law Gazette publication was pending at time of writing. This content does not constitute legal or financial advice.

Frequently asked questions (FAQs)

The rebate rises from 7% to 15.5% of the ex-VAT list price, effective 1 January 2027. This replaces the dynamic formula proposed in the April draft.

The 15.5% rebate and the vaccine measures apply from 1 January 2027. The removal of AMNOG price guardrails, the tendering pilot and the combination discount abolition take effect the day after the law is published in the Federal Law Gazette.

No. Unlike the April draft, which proposed a phased start at 10.5% for the first half of 2027, the final law applies the full 15.5% from day one, with no ramp-up period.

Biosimilars and their reference biologics are exempt. New active substances launching from 2027 can also qualify for a location-clause exemption if at least 5% of clinical trial participants are enrolled at German sites; this runs for three years and is renewable. Beyond the formal exemptions, the law leaves one further route open, known as supersession. It is not an exemption, but it can remove the additional 8.5 points where the reimbursement price is agreed on the right terms.

About the authors:
Brett Gardiner

Brett is a Senior Partner at Access Infinity and brings a unique combination of clinical and academic expertise in immunology and genetics to his role in pricing and market access. He possesses a proven track record of success, managing and contributing to the development of pricing and reimbursement strategies for over 200 biopharmaceuticals, vaccines, and medical devices across all product life cycle stages.

Emily Hall

Emily is an Associate Director at Access Infinity. Her consulting experience focusses on pricing and access strategy across diverse disease areas and global markets. She has led multiple projects involving extensive secondary, primary and quantitative research to support clients determine pricing and access potential, clinical trial design and launch sequencing for early and late-stage assets. 

Categories
Blog

Measuring payer engagement impact on market access KPIs

How local implementation strategies and payer engagement quality can influence time to access, breadth of access, and price – and what pharmaceutical companies can do about it.

A successful market access launch is typically measured against three KPIs: time to access, breadth of access, and price. But these metrics only tell part of the story. The hidden drivers – payer perception, engagement quality, and message recall – can directly influence whether those KPIs are ever met. Without a structured feedback loop to capture these softer signals, country teams are left making tactical decisions in the dark.

The traditional access triangle: necessary but not sufficient

When a pharmaceutical company launches a new product or indication, global teams set a market access strategy anchored in a familiar framework: the Access Triangle. Regional and local teams are then responsible for translating that global strategy into tactical, actionable implementation plans.

The three KPIs are:

  • Time to access – how quickly is reimbursement achieved?
  • Breadth of access – which patients or geographies are covered?
  • Price – was the manufacturer’s target price achieved or maintained

The outcome of these KPIs is black and white – they are either met or not met. If they are met, everyone is happy. If not, there is rarely a structured feedback loop to help country teams understand the subjective drivers behind that shortfall. In most cases, at least one of those three KPIs will require some degree of compromise – but without understanding why, the same mistakes are repeated.

The hidden obstacles influencing market access outcomes

Beyond clinical evidence and value dossiers, there are more subtle, psychological and relational factors at play. These include:

  • Payer perceptions of the manufacturer – a single negative engagement in the past, or a perception of low trustworthiness, can unconsciously colour reimbursement decisions.
  • Frequency and quality of payer communications – too frequent, and payers feel overwhelmed; too infrequent, and the manufacturer risks being forgotten.
  • Channel appropriateness – a cold call to a busy hospital pharmacist may be disruptive and counterproductive. The right message in the wrong channel can undermine an otherwise strong engagement strategy.
  • Message recall and competitor benchmarking – if payers cannot recall your product’s key value messages but can recall a competitor’s, your product is not top of mind when reimbursement decisions are made.
  • Corporate reputation and portfolio perception – do payers view your company as trustworthy? Do they consider your portfolio worthwhile? These broader perceptions feed indirectly into how individual products are received.
“If the overall engagement strategy isn’t relevant for the stakeholder - if the channel of communication isn’t appropriate, or the frequency of contact isn’t appropriate - then that could tarnish the entire customer relationship and consequently impact the outcome of a reimbursement decision, unconsciously.”
Megan O'Brien
Associate Director, Access Infinity

How market access teams currently engage with payers

Most access teams today use some form of omni-channel engagement. The most common channels are:

  • Face-to-face meetings – still preferred in many markets and cultural contexts, particularly for high-stakes conversations.
  • Phone calls – useful for follow-up and relationship maintenance, though timing and context matter.
  • Email – often the preferred first point of contact, particularly for stakeholders with busy clinical schedules.
  • Digital and indirect channels – including LinkedIn, targeted advertising, and webinars, which are growing in relevance post-pandemic.

The mix of channels used, and how they are sequenced, can significantly affect the quality of the payer relationship. Yet most companies do not systematically measure whether their chosen engagement approach is actually working.

Why the current feedback loop is not enough

There is a traditional feedback loop in market access: value message testing, health technology assessment outcomes, and reimbursement decisions. These are valuable, but they are lagging indicators. They tell you what happened – not why, and not what you could do differently.

What is largely missing is a structured mechanism to capture:

  • How payers perceive the manufacturer as a partner, not just a supplier
  • Whether communications are seen as relevant, timely, and trustworthy
  • How the company’s engagement compares to that of competitors
  • Whether payers can recall the brand’s key value messages

Without this insight, country teams are left making tactical decisions in the dark – unable to course-correct before a reimbursement outcome crystallises.

How to start measuring payer perception: a practical approach

The most effective way to build this missing feedback loop is through impartial, structured primary research – commissioned from a third party to ensure objectivity.

Step 1:
Define what you want
to measure

  • Corporate perception: trustworthiness, social responsibility, portfolio value
  • Engagement quality: frequency, relevance, channel appropriateness
  • Message recall: can payers name your product’s key value claims unprompted?
  • Competitive benchmarking: how do you compare to other manufacturers?

Step 2:
Select the right research methodology

  • Qualitative interviews with payer decision-makers to uncover nuanced perceptions
  • Quantitative surveys to benchmark performance across markets and against competitors
  • Advisory boards facilitated by a neutral third party to capture candid feedback

Step 3:
Analyse findings against KPI performance

  • Overlay perception data with access outcomes by country or region
  • Identify correlations between low payer trust scores and delays in time to access
  • Use findings to prioritise where engagement strategy changes will have the biggest impact

Step 4:
Connect insights to tools
like Access Hub

  • Platforms like Access Hub already track reimbursement status and price across markets
  • Combining this with perception data creates a richer picture of what is driving outcomes – not just what the outcomes are
  • This enables global teams to learn from high-performing countries and support those that are struggling

Hear from the experts at Access Infinity

Listen to the Market Access Matters podcast with Megan O’Brien, Associate Director at Access Infinity, to hear more about how payer perception shapes market access outcomes – and what teams can do about it.  

Listen now.

Frequently Asked Questions

Payer perception refers to how healthcare payers – such as national reimbursement bodies, hospital formulary committees, or regional health authorities – view a pharmaceutical manufacturer and its products. Perception influences trust, which in turn shapes how receptive payers are to value messages and reimbursement submissions. A negative perception, even from a single poor engagement experience, can unconsciously bias decision-making.

Value message testing evaluates whether specific clinical or economic claims land as intended – are they clear, credible, and relevant? Payer perception research goes further, examining the broader relationship between the manufacturer and the payer: trust, engagement quality, communication frequency, channel preference, and competitive standing. Both are important, but most companies do the former without ever doing the latter.

Ideally, perception research should be conducted at key milestones: before a launch to establish a baseline, at the time of HTA submission, and post-launch to identify areas for improvement. In competitive therapy areas, annual (or more frequent) benchmarking may be appropriate to track shifts over time.

Yes, and this is one of the key benefits. Global and regional teams can use perception data to identify which countries have the strongest payer relationships and what they are doing differently – then share those best practices with markets that are underperforming. Connecting this data to a tool like Access Hub makes it even more actionable.

Conclusion

Meeting the Access Triangle KPIs remains the ultimate measure of market access success. But relying solely on black-and-white outcomes – without understanding the subjective drivers behind them – leaves teams without the insight they need to improve. By building a structured feedback loop around payer perception, engagement quality, and message recollection, pharmaceutical companies can provide local teams with the tools to engage more effectively, communicate more memorably, and ultimately achieve better reimbursement outcomes.

Want to find out how your payer engagement strategy measures up?

At Access Infinity, we help pharma companies understand the hidden drivers behind their market access outcomes, from payer perception research to actionable engagement strategies.

Get in touch with our team here to discuss your specific needs.

About the author

Megan is an Associate Director at Access Infinity with nearly 15 years of pharmaceutical consultancy experience, specialising in pricing and market access, real-world evidence generation, and business intelligence. She has led strategic partnerships for major pharmaceutical clients and offers deep expertise into the world of payers and market access strategy across global markets. Megan has also designed and delivered single- and multi-sponsor non-interventional RWE studies, delivering pragmatic, evidence-based solutions to address complex market access challenges designed to meet the needs of payers.

If you have a question or a project in mind, get in touch with Megan by emailing megan@accessinfinity.com or via our contact us page.

Categories
Blog

Germany’s GKV-BStabG reform: what it really means for pharma

Seven provisions. Two that help industry. Five that do not. A structured assessment of what was proposed, what is likely to pass, and what pharma companies need to do now.

On 29 April 2026, the German Federal Cabinet formally adopted the GKV-BStabG, the most significant structural change to German pharmaceutical market access in over a decade. With the statutory health insurance system projected to run a €15.3 billion deficit in 2027, the pharmaceutical sector is expected to contribute approximately €1.7 billion toward a €16.3 billion savings target. Core provisions take effect from 1 January 2027.

The legislative process has moved at exceptional speed. The formal stakeholder consultation was compressed into just 72 hours. Final parliamentary approval is targeted before the summer recess in early July 2026, leaving a narrow window for industry response.

What’s in the GKV-BStabG reform

The reform contains seven distinct provisions affecting pharmaceutical pricing and market access. The centrepiece is a dynamic manufacturer rebate that replaces the current fixed 7% rate with a variable, uncapped mechanism linked to GKV drug expenditure growth. Industry consensus projects the total rate at approximately 20% by 2030.

Alongside this, the reform introduces selective tendering for patented drugs for the first time, a statutory fallback for volume-based pricing, and new stacked rebates for vaccines. On the positive side, it removes the 2022 AMNOG price guardrails and abolishes the 20% mandatory combination discount on brand-brand therapies.

What’s at stake with the GKV-BStabG reform

Every P&MA team with German market exposure needs to understand which provisions will pass as drafted, which are likely to be narrowed, and how the combined effect reshapes the economics of patented products in Germany. The answers vary significantly by therapy area, portfolio composition, and where products sit in their lifecycle.

Read the full analysis

Our full whitepaper provides provision-by-provision analysis with Access Infinity’s independent assessment, passage probability for each measure, scenario modelling guidance, identification of the most affected companies and therapy areas, and a detailed action plan for P&MA teams.

Download the whitepaper

 

This blog is prepared by Access Infinity for informational purposes. All provisions described reflect the GKV-BStabG Kabinettsentwurf of 29 April 2026. The legislation remains subject to parliamentary amendment. This content does not constitute legal or financial advice.

About the authors:
Brett Gardiner

Brett is a Senior Partner at Access Infinity and brings a unique combination of clinical and academic expertise in immunology and genetics to his role in pricing and market access. He possesses a proven track record of success, managing and contributing to the development of pricing and reimbursement strategies for over 200 biopharmaceuticals, vaccines, and medical devices across all product life cycle stages.

Emily Hall

Emily is a Senior Consultant at Access Infinity. Her consulting experience focusses on pricing and access strategy across diverse disease areas and global markets. She has led multiple projects involving extensive secondary, primary and quantitative research to support clients determine pricing and access potential, clinical trial design and launch sequencing for early and late-stage assets. 

Categories
Blog

The Four Dimensions of Analogue Analysis in Rare Diseases

Analogue analysis in rare diseases plays a central role in how we think about value, evidence and positioning for orphan therapies. It shapes pricing strategy, HTA positioning and value communication; yet in rare diseases, analogue assessment is rarely straightforward.

Unlike established therapy areas with clearly defined treatment pathways, orphan drug development often lacks a single obvious reference point. Evidence standards vary, endpoints may be unfamiliar to payers, and patient populations are small or heterogeneous.

Analogue assessment for orphan drugs is more like assembling a puzzle: no individual piece gives you the full picture, and the way the pieces are chosen and fitted together ultimately determines the quality of the answer.

Fortunately, I’ve always been a fan of puzzles. I find the process of laying out the pieces, testing different combinations, and slowly arriving at something coherent deeply satisfying. Perhaps that’s why rare diseases have come to occupy so much of my work.

A structured, question-led analogue scorecard approach can improve transparency, defensibility and strategic alignment when selecting comparators for rare disease HTA and pricing decisions.

Why Analogue Analysis Is More Complex in Rare Diseases

In common diseases, analogue selection typically follows predictable patterns. Standards of care are well established. Historical precedents exist. Payers are familiar with clinical endpoints and benchmarks.

In rare diseases, those anchors are often absent. The challenges orphan medicines face are quite different from those in non-orphan indications:

  • Limited or evolving standard of care
  • Small and heterogeneous patient populations
  • Novel or surrogate endpoints
  • Uncertainty around long-term durability of benefit
  • Variable HTA precedents across markets

As a result, searching for a single “perfect” analogue can be misleading, if not impossible. At best, it risks oversimplifying the value story. At worst, it leads teams to abandon analogue research altogether because nothing seems to fit.

For orphan medicines, analogue analysis must be multi-dimensional.

Analogue assessment as a puzzle, not a match

Thinking about analogue research as a puzzle helps reframe the task. Rather than identifying one closest match, effective analogue analysis assesses multiple potential comparators across defined strategic dimensions. The objective is not to identify the best analogue overall, but the most informative analogue for a specific decision.Teams often default to referencing high-profile orphan drug successes. However, using a single comparator to inform pricing or HTA strategy risks oversimplification. One analogue may be helpful for understanding evidence standards. Another may offer insight into endpoint relevance. A third may help frame expectations around target population size or unmet need.

No single comparator answers everything: I’ve lost count of the number of times I’ve had to gently wave Zolgensma away as an analogue. Not because it isn’t a remarkable success story, but because it simply isn’t the right reference for every situation.

The strength of analogue assessment lies in structured comparison, not intuitive selection.

A Question-Led Framework for Comparator Selection

Effective analogue analysis begins with a clearly defined strategic question:

  • Are we assessing pricing potential?
  • Are we testing payer acceptability of the evidence package?
  • Are we informing clinical development strategies?
  • Are we shaping value communication?

Different questions require different lenses. A structured analogue scorecard makes this explicit.

The Four Dimensions of a Rare Disease Analogue Scorecard

At its core, the rare disease analogue scorecard evaluates potential comparators across four consistent dimensions.

Adjusting the Strategic Lens

As previously mentioned, the same analogue may be highly informative in one context and less relevant in another. A defining feature of a structured analogue analysis scorecard is dynamic weighting depending on the strategic question.

For example:

  • When assessing pricing and value framing, nature and magnitude of benefit may carry greater weight.
  • When evaluating HTA risk, the evidence package may be the dominant consideration.
  • When informing development strategy, population definition and endpoint alignment may take precedence.

Weighting does not produce a single definitive answer. Instead, it clarifies why a comparator is relevant for a particular strategic question, and makes it clear why the same analogue may be highly relevant in one context and much less so in another. This improves cross-functional alignment and strengthens internal and external defensibility.

Practical Implications for Rare Disease Market Access Strategy

In practice, a structured analogue scorecard approach enables:

  • More transparent and defensible comparator selection
  • Clear articulation of strategic assumptions
  • Stronger alignment between global and local teams
  • Better justification of pricing recommendations
  • Improved anticipation of HTA scrutiny

Importantly, it does not remove uncertainty. It makes uncertainty explicit, structured and easier to navigate.

From Analogue Research to Strategic Capability

In rare diseases, analogue analysis should not be treated as a shortcut to pricing; it is a strategic capability.

When applied rigorously, analogue assessment supports:

  • Early value assessment
  • Evidence generation planning
  • Pricing corridor modelling
  • HTA scenario planning
  • Value communication strategy

For orphan medicines, where precedent is limited and scrutiny high, structured analogue analysis provides discipline without oversimplification. The result is not a single “right” analogue, but a more thoughtful, transparent, and credible decision-making process

Download the Rare Disease Analogue Scorecard

If you would like a structured template for applying this framework, a downloadable rare disease analogue scorecard and example analysis is available on request.

Scorecard image

Download the resource

 
About the author

Isabel is a Partner at Access Infinity and has supported pharma companies in developing their Pricing & Market Access strategy for products across all major therapeutic areas. She’s worked with several orphan drug manufacturers from the earliest stages of drug development through to launch readiness, to ensure the value of their therapies is recognised by payers.

If you have a question or a project in mind, get in touch with Isabel by emailing isabel@accessinfinity.com or via our contact us page.

Frequently Asked Questions

Analogue analysis in rare diseases is a structured framework used to evaluate comparable orphan medicine launches across defined dimensions to inform pricing, HTA strategy and value positioning.

Rare diseases often lack established standards of care, involve small patient populations and use novel endpoints, making direct comparison complex and multi-dimensional.

HTA bodies typically evaluate the competitive landscape, nature of benefit, robustness of evidence, and clarity of target population when assessing comparability.

No. A structured approach evaluates multiple comparators across defined dimensions, weighted according to the strategic question being addressed.

Categories
Blog

AI in Market Access: Why Successful Adoption Starts with the Problem

Artificial intelligence is becoming a major focus across pharmaceutical market access, health economics and outcomes research, and evidence generation. Organisations are exploring how AI can accelerate literature reviews, support evidence synthesis, and assist with the development of HTA submissions. This reflects growing artificial intelligence in pharma initiatives and practical pilots for AI in evidence generation.

Yet many companies are still determining where AI can deliver meaningful value, making ai adoption in pharma a measured, stepwise process.

During a recent discussion at the World EPA Congress, moderated by Thomas Gilboy, industry leaders shared practical perspectives on how organisations are approaching AI in market access today.

While the conversation covered a range of potential applications, one message emerged clearly. Organisations making real progress are not starting with the technology. They are starting with clearly defined problems and then evaluating whether AI can help solve them.

Key takeaways: AI in market access

Artificial intelligence is generating significant interest across pharmaceutical market access and evidence generation. However, successful AI adoption requires a focused and practical approach. 

Key lessons emerging from industry discussions include:

  • Organisations should start with clearly defined problems rather than adopting AI for its own sake
  • Targeted use cases such as literature monitoring and evidence synthesis often deliver the most immediate value
  • Human expertise remains essential when interpreting evidence and developing value narratives
  • Many AI tools in pharma are still evolving and require careful evaluation through pilot projects
  • Strong evidence management foundations help organisations maximise the value of AI technologies. 

Start with the problem, not the technology

Artificial intelligence in pharma is often presented as a transformative solution across life sciences. However, adopting AI simply because it is available can create unnecessary complexity.

Before introducing new tools, organisations need to define the operational challenges they want to address. These challenges might include managing large volumes of published evidence, identifying relevant insights across multiple data sources, or improving the efficiency of evidence synthesis.

In some cases, the most effective solution may not involve AI at all. Automation, improved workflows, or stronger data management practices can sometimes deliver faster, more effective improvements.

Organisations that begin by clearly defining the problem are far more likely to identify situations where AI can genuinely support market access teams.

Focus on targeted use cases for AI in evidence generation

Rather than launching large scale AI transformation programmes, many organisations are exploring smaller and more focused applications.

For AI in pharma teams, evidence monitoring is one example. Market access teams frequently review large volumes of scientific literature to identify emerging data that could influence value dossiers or HTA submissions. AI tools can help scan publications and highlight potentially relevant findings more quickly.

However, the most successful initiatives focus on specific tasks within the evidence generation process. By breaking complex workflows into smaller components, organisations can identify where AI can improve efficiency without introducing unnecessary risk.

This approach allows teams to test AI capabilities, measure their impact, and expand successful use cases over time.

AI can support evidence review but human expertise remains essential

Despite rapid progress in artificial intelligence, human expertise remains central to market access strategy.

AI can assist with tasks such as summarising research findings, identifying inconsistencies in documents, or organising information across large datasets. In some cases, AI tools may highlight issues that human reviewers initially overlook.

However, developing the narrative behind an evidence dossier or HTA submission requires strategic interpretation. Market access teams must decide which data points are most relevant, how evidence should be positioned, and what message the overall evidence package should communicate.

These decisions depend on experience and contextual understanding. AI can support this work, but it cannot replace the expertise required to interpret evidence and communicate value effectively.

Many AI tools in pharma are still evolving

Another important theme emerging across the industry is the maturity of AI solutions.

Technology vendors often demonstrate impressive capabilities, but real-world performance can vary significantly. Some tools remain exploratory, while others require substantial validation before they can be integrated into existing workflows. As AI in pharma initiatives expand, careful validation remains essential.

For this reason, organisations are increasingly adopting a cautious approach. Pilot projects allow teams to evaluate AI tools in controlled environments and understand both their benefits and limitations.

This experimentation is essential for identifying where artificial intelligence can deliver meaningful improvements in evidence generation and market access processes.

Building a practical roadmap for AI in market access

While organisations are taking a measured approach, interest in AI across pharma market access continues to grow.

Many teams are developing structured roadmaps to guide their adoption of artificial intelligence. These roadmaps often include identifying priority use cases, testing technologies through pilot projects, and scaling successful initiatives once they demonstrate measurable value.

This approach allows organisations to explore AI while remaining focused on the practical challenges faced by market access and HEOR teams, and it supports thoughtful AI adoption in pharma.

This experimentation is essential for identifying where artificial intelligence can deliver meaningful improvements in evidence generation and market access processes.

The growing role of evidence management platforms

As access teams continue to explore AI, many are also rethinking how evidence is managed across the product lifecycle.

Market access and HEOR teams work with large volumes of clinical, economic, and real-world evidence. This information is often stored across multiple systems and internal repositories, making it difficult to identify relevant data when preparing value dossiers, publications, or HTA submissions.

Evidence management platforms help address this challenge by providing a structured environment where evidence can be organised, curated, and reused across market access activities.

When combined with AI capabilities, these platforms can support activities such as:

  • Identifying relevant evidence across large datasets
  • Supporting literature monitoring and evidence synthesis
  • Highlighting potential inconsistencies across documents
  • Accelerating the development of evidence packages for HTA submissions. 

The effectiveness of AI in market access often depends on the quality and accessibility of the underlying evidence. Organisations that invest in stronger evidence management foundations are therefore better positioned to benefit from artificial intelligence.

Deep dive: AI adoption in pharma and market access

To explore this topic further, watch the on-demand webinar presented by Tom Gilboy.

In the session “AI Adoption: When It Helps, When It Hurts and How To Decide,” Tom explores how organisations can evaluate artificial intelligence. The webinar examines where AI can realistically support value, access & pricing teams and highlights common challenges organisations encounter when adopting new technologies.

Watch the webinar on-demand here. 

Categories
Blog

Navigating the PD-(L)1 Patent Cliff: The future of oncology pricing

The oncology landscape is approaching a critical inflection point. Between 2028 and 2035, patent protection for the industry’s most significant PD-(L)1 checkpoint inhibitors will expire across global markets. As these “economic anchors” face biosimilar entry, the fundamental benchmarks for oncology pricing and reimbursement are set to be rewritten. 

For Pricing and Market Access teams, this transition represents more than a standard loss-of-exclusivity cycle; it is a total reset of the solid-tumor therapeutic landscape 

Why This Shift Demands Proactive Strategy

PD-(L)1s currently serve as the backbone of modern cancer care, dictating how entire healthcare budgets are structured. When the net price of these backbones drops, it creates a ripple effect across the entire sector: 

  • Regional Pricing Divergence: Anticipate varied erosion speeds, from the “fast and deep” hospital tenders of Europe to the stepwise evolution of PBM strategies in the United States. 
  • The Subcutaneous Wildcard: Early launches of SC formulations are creating “defensive moats,” shifting the value conversation from drug cost to clinic efficiency and patient chair time.
  • Combination Therapy Economics: As PD-(L)1 prices fall, the room for innovative add-ons (such as ADCs) expands, but the cost of key clinical benchmarks also falls. 

Hear from the Experts at Access Infinity

Access Infinity’s insights, taken from years of working with pharmaceutical and biotech companies on oncology market access strategy, reveal the complexity of this transition. The analysis breaks down the patent cliff timeline, examines how different markets will respond, and explores what this means for manufacturers across the competitive landscape. 

What’s Inside the Full Analysis

The analysis covers key aspects of the PD-(L)1 biosimilar transition, including: 

  • Detailed patent expiry timelines for Keytruda, Opdivo, Imfinzi, and Tecentriq across major markets 
  • How biosimilar entry will play out differently across Europe, the United States, and Japan 
  • The role of subcutaneous formulations in the competitive landscape 
  • Strategic considerations for originator manufacturers, biosimilar developers, and innovators launching combination regimens 
  • Where PD-(L)1s underperform and areas of opportunity 
  • Actionable steps to take a proactive approach for pricing and access leaders 

Download the Analysis Today​

The PD-(L)1 Patent Cliff: What It Means for the Future of Oncology Pricing is a great resource for market access, HEOR and pricing teams navigating lifecycle planning and pricing in oncology. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast and Policy Insights. You can also find out more in our on-demand webinars.

Gain deeper insights into the PD-L1 patent cliff and prepare your strategic thinking for the oncology pricing reset. Fill out the form below to receive your copy. 

Download the resource

About the author

George has over eight years’ experience delivering strategic pricing and market access projects, supporting manufacturers with launch excellence planning and lifecycle management. He has worked extensively with companies seeking to commercialise late PD-(L)1 entrants, both as monotherapies and in combination regimens, as well as with manufacturers aiming to compete effectively within crowded oncology markets.

If you have a question or a project in mind, get in touch with George by emailing George@accessinfinity.com or via our contact us page.

Categories
Blog

Mastering US Market Access: A One-Day Course with CELforPharma

The US pharmaceutical market represents the single greatest commercial opportunity for life sciences companies worldwide, but it’s also one of the most challenging to navigate successfully.

A fragmented payer landscape, evolving policy frameworks, and diverse stakeholder incentives create significant hurdles for even the most promising therapies. From the Inflation Reduction Act to PBM transparency requirements and Most Favoured Nation Pricing, the rules of engagement are shifting rapidly and global teams need to understand these dynamics to build effective pricing and access strategies.

That’s why we’re excited to share that two of our senior experts, Nick Proctor and Louisa Oliver Byrne, are running a comprehensive one-day course on Understanding Pharma Market Access in the US with CELforPharma on 22nd October.

Why This Course Matters

This session offers a practical, in-depth look at how US market access operates, tailored for global and cross-functional professionals who need to understand its complexities. Whether you’re in Medical Affairs, Marketing, Clinical Development, Health Outcomes, or transitioning from an in-country role to a global position, this course provides the essential foundation you need.

Nick brings over 25 years of pricing and reimbursement expertise, including extensive on-the-ground experience working with US payers and supporting major product launches. Louisa leads our US Managed Care Centre of Excellence and specialises in access strategy, value story development, and evidence generation tailored to US stakeholders. Together, they’ve authored resources including Market Access in the IRP Era, and Louisa has explored critical policy topics like MFN pricing in depth through our podcast series.

They’ll guide you through the key players, systems, and decision-making processes that determine market access outcomes and equip you with practical frameworks to navigate them effectively.

What Participants Are Saying

“This is one of the best Market Access trainings I have taken. The course materials were excellent, concise, and very well-structured… The pace of the course and the balance with questions and answers were perfect!”
—

Oramon Nimkannon, Capability Lead Pricing & Contracting

Boehringer Ingelheim

 

“I can highly recommend this course! Nick and Louisa gave a very clear presentation of the US Market Access systems.”
—

Florian Toussaint, Market Access and Public Affairs Manager

GSK

Ready to Master US Market Access?

Don’t miss this opportunity to learn from two of our subject matter experts in an interactive, discussion-rich format.

Register now for the CELforPharma US Pharma Market Access course and gain the insights you need to drive success in the world’s most important pharmaceutical market.

Dive Deeper Into US Policy Changes

Want to understand the implications of Most Favoured Nation pricing before the course? Louisa recently explored this complex topic in our podcast Beyond the Headlines: Understanding MFN’s True Impact on Market Access, breaking down what these policy shifts really mean for pricing and access strategies.

And if you’re navigating the intersection of US pricing decisions and international reference pricing, our resource Market Access in the IRP Era provides essential insights into managing global pricing strategies in an increasingly interconnected landscape.

Download 'Market Access in the IRP Era'

Categories
Blog US Pricing Policy

Facing the International Reference Pricing Era: How to Respond to Global Pricing Disruption

Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future, is a strategic resource exploring how U.S. drug pricing could change if new international reference pricing (IRP) policies take hold. Using a sample portfolio, we model potential impacts across multiple scenarios to help market access teams prepare for what may come next.

Understanding the Evolving IRP Landscape

A May 2025 Executive Order has reignited the debate around MFN pricing, with the potential to tie US drug prices to what other high-income countries pay. This isn’t just policy speculation, it’s a regulatory shift that could fundamentally alter pharmaceutical economics worldwide.

The concept isn’t new. Previous MFN proposals faced significant legal challenges, but the current political climate and growing pressure on drug prices have brought International Reference Pricing (IRP) back into sharp focus. The difference now? The potential for implementation feels more real than ever.

For market access teams, this represents uncharted territory. How do you prepare for a policy that could reshape everything from launch sequencing to pricing strategies? How do you model impacts when the implementation details remain unclear?

Hear from the experts behind Access Infinity

Access Infinity’sinsights, taken from years of working with top-tier pharma companies and deep regulatory analysis, paint a clearer picture of what IRP implementation could mean for the industry. Our experts break down the May 2025 Executive Order and modelled its potential impacts across different implementation pathways.

What the analysis will cover

The analysis addresses some of the most pressing questions facing market access teams today, including:

  • Breaking down the executive order and its implications
  • Two critical scenarios for IRP implementation
  • Real portfolio impact modelling with patient cost analysis
  • Strategic responses for manufacturers and payers
  • Launch sequencing strategies to protect pricing power
  • Long-term implications for global pharmaceutical markets

Why scenario planning matters now

While regulatory uncertainty has always been part of pharmaceutical strategy, the potential for International Reference Pricing and MFN policy implementation represents a paradigm shift that demands immediate attention. So how can market access teams prepare for multiple outcomes and position themselves strategically?

Historically, while teams have planned for incremental policy changes, MFN pricing could fundamentally alter the economics of pharmaceutical innovation. Our new analysis showcases exactly why scenario-based planning is essential, helping teams prepare for disruption while identifying opportunities within regulatory change.

The analysis reveals that smart strategic positioning today could mean the difference between protecting market position and facing significant revenue erosion. From launch sequencing tactics to pricing optimisation strategies, there has never been a more crucial time to think ahead of regulatory change.

Likewise, understanding both the direct-to-consumer and channel disruption scenarios gives market access teams the competitive advantage they need. This analysis shows how to navigate uncertainty while maintaining strategic flexibility for whatever emerges.

Download the analysis today

‘Market Access in the IRP Era: Scenarios to Plan for an Uncertain Future’ is essential reading for market access teams that want to stay ahead of regulatory change. It comes as just one of many expert resources from Access Infinity, including our ‘Market Access Matters’ podcast. You can also find out more in our on-demand webinars.

Gain deeper insights and plan for an uncertain but strategic future. Fill out the form below to receive your copy.

Download the resource

Categories
Blog

Breaking Through Barriers: How Innovation is Revolutionising Orphan Drug Development

Developing orphan drugs is a uniquely complex challenge; one that goes far beyond trial design. Demonstrating efficacy is often constrained by small patient populations, variable disease progression, heterogeneous symptoms, and ethical limitations around placebo use. But the hurdle isn’t just running a gold-standard trial; it’s building a comprehensive evidence package in the face of inevitable data gaps.

A lack of consensus on clinical guidelines, reimbursed treatment pathways, validated endpoints, and patient-reported outcomes only adds to the difficulty. And this isn’t just important for manufacturers.  It’s critical for patients, who often have few (if any) other treatment options. When the stakes are this high, both scientific rigor and patient experience must be at the centre of the development process.

This creates a challenging reality for orphan drug developers because unlike common disease drugs, orphan treatments rarely get a second chance. The small, finite patient population makes re-trials nearly impossible, so a trial design that considers payer requirements is not only advisable but essential. A single misstep in trial design can compromise reimbursement and pricing prospects.

Perhaps the most crucial insight from recent orphan drug successes is this: regulatory approval is just the beginning. For many rare disease treatments, the real challenge lies in demonstrating value to payers and health technology assessment bodies – and their requirements often differ dramatically from regulatory expectations.

There’s good news though. Manufacturers are increasingly drawing on past learnings to shape more robust trial strategies. This growing body of knowledge is driving innovative and creative approaches to endpoint design, evidence presentation, and outcome-linked payment models.

It’s a subject that fascinates us. So, in this blog post, Access Infinity Partner Isabel Rubio explores orphan drug development’s complexities, evidence presentation opportunities, and how developers can strategically leverage outcome-based agreements with the data they have.

Three Game-Changing Strategies Reshaping the Field

1. The Multi-Domain Revolution: When One Size Doesn’t Fit All

The traditional approach to clinical endpoints has been rigid: define one primary measure of success and apply it uniformly to all patients. But rare diseases don’t necessarily follow these rules. The heterogeneity of many genetic orphan diseases means a child might show improvement in mobility while another has gains in vision or respiratory function.

Enter the multi-domain, responder-based endpoint: a flexible approach that allows patients to demonstrate meaningful improvement in any of several clinically relevant areas. Instead of forcing every patient through the same narrow measure of success, this method recognises that clinical benefit can manifest in multiple ways.

This is nothing new; multi-domain endpoints have been utilised across a range of therapeutic areas, from cardiovascular to neuromuscular indications. From a clinical perspective, this approach makes sense, especially in the context of diseases where symptoms are heterogeneous. But what happens when the symptoms are not only heterogeneous, but also misunderstood? Or when there is no validated, gold-standard multi-domain metric?

When it comes to these situations, payers are also in the dark. The good news is that manufacturers have the opportunity to work with the clinical community to define these metrics. However, the clinical point of view is not the only one that matters here; payers should get the chance to provide input into what these endpoints should cover, or what the hierarchy should be. No manufacturer wants to find themselves with a primary endpoint measuring behavioural changes, only to find payers place more value on cognitive improvements.

The challenges don’t stop at choosing a scale. In the absence of a recognised benchmark, payers will scrutinise what degree of change on that scale constitutes real clinical benefit. It falls to the manufacturer to set that threshold, taking national requirements into account. For instance, French authorities usually expect a two-point advantage over the control arm, not merely an improvement from baseline.

This is especially relevant in cases where there is not a gold standard scale for a disease, as is usually the case for orphan conditions with no treatment available. Beyond considering payers’ feedback, manufacturers should work together with their medical teams to build consensus on new scales and domains and educate payers on the clinical meaning behind point-based improvements. This leads us to our second strategy.

2. A Picture Worth a Thousand Data Points: The Power of Visual Evidence

The progressive and heterogeneous nature of many orphan diseases can sometimes make an improvement on paper difficult to understand for payers. Increasingly, payers want tangible outcomes, evidence of improvement that they could easily explain to the family of a patient. For example, a parent is not going to get excited about the fact that a new innovative therapy may result in a “three-point improvement” in motor skills, measured through a scale known by a series of letters and dashes. They will, however, feel optimistic if they know that their child will now be able to hold a pencil and write their name. 

Sometimes, the most compelling evidence isn’t found in spreadsheets or statistical analyses, it’s captured on video. Take an already-launched groundbreaking gene therapy for inherited blindness. While visual field tests provided important clinical data, it was the dramatic footage of treated patients navigating obstacle courses that truly demonstrated the treatment’s life-changing impact. 

This multimedia approach to evidence isn’t just emotionally compelling; it’s becoming increasingly accepted by health technology assessment agencies worldwide. Videos have been successfully used not only during clinical evaluation but also in price negotiations (even with bodies like the GKV-SV), fundamentally shifting how payers perceive treatment value. 

3. Thinking Beyond the Trial: Designing Endpoints for the Real World

We get it: demonstrating value through clinical trial outcomes and multimedia may not be enough. Despite teams’ efforts, payers may be reluctant to accept the claims of efficacy for an innovative treatment, citing uncertainties in long-term efficacy and safety. This may translate into P&MA conditions that don’t fully reflect the value developers see in their products. This is where outcomes-based agreements come in. We would be naïve to refer to these types of agreements as “innovative”, given they have been around for several years. However, they remain underutilised, but not for lack of trying.

Payers cite two key issues when it comes to outcomes-based agreements: burdensome tracking of patients and difficulty designing an agreement linked to subjective efficacy endpoints. In the case of orphan drugs, the first issue does not apply. The second, however, is more prominent than in non-orphan drugs, and can remain a major hurdle for developers and payers alike.

Here’s where many orphan drug developers make a common mistake: they treat clinical trial endpoints and post-launch reimbursement as separate challenges and don’t consider whether the selected endpoints will be a good fit for an outcomes-based agreement, should they need one. If these endpoints can’t be reliably measured in routine clinical practice, a strategy that could be banking on a payment by results collapses.

The solution is deceptively simple. Design trial endpoints with real-world accountability in mind from day one. This means selecting measures that are objective, easily trackable in routine care, and clinically meaningful to both physicians and patients.

The Path Forward: From Obstacles to Opportunities

The challenges facing orphan drug development haven’t disappeared, but the industry’s response has been nothing short of remarkable. By embracing flexible endpoint design, multimedia evidence, real-world accountability, and early stakeholder engagement, developers are finding ways to demonstrate value even in the most constrained circumstances.

These innovations aren’t just changing how we develop treatments for rare diseases; they’re creating a new paradigm that could benefit all of healthcare. The patient-centred, flexible approaches pioneered in orphan drug development are beginning to influence trial design across therapeutic areas.

The Bottom Line

Developing treatments for rare diseases will never be easy. The key lies in recognising that orphan drug trials must do more than prove efficacy. They must tell a compelling story to all stakeholders using the metrics that matter most to them.

For the millions of patients worldwide living with rare diseases, these methodological innovations represent more than academic progress. They represent hope that the next breakthrough treatment won’t just work in theory but will reach the patients who need it most.

The future of orphan drug development isn’t about overcoming constraints. It’s about turning those constraints into catalysts for innovation. And for patients with rare diseases, that innovation can’t come soon enough.

About the author

Isabel is a Partner at Access Infinity and has supported pharma companies in developing their Pricing & Market Access strategy for products across all major therapeutic areas. She’s worked with several orphan drug manufacturers from the earliest stages of drug development through to launch readiness, to ensure the value of their therapies is recognised by payers.

If you have a question or a project in mind, get in touch with Isabel by emailing isabel@accessinfinity.com or via our contact us page.